高管现金保留计划披露后，Karyopharm股价下跌21%

2026-07-21 04:57

Karyopharm Pharmaceuticals (KPTI) closed Monday down ~21% after disclosing a "2026 Leadership Cash Retention Program" for some of its top executives.
Those who will benefit from it are its CEO, CFO, chief development officer, and chief medical officer.
CEO Richard Paulson is the largest beneficiary as he will receive $1,725,000.
An SEC filing stated that the purpose of the program is "to incentivize retention of key employees during a period in which the Company is expecting several meaningful catalysts requiring the continued experience and expertise of the designated employees."
RBC Capital Markets, which rates the stock at outperform and a $16 price target (~128% upside based on Monday's close) said the sell-off is unwarranted based on conversations it had with the company.
Analyst Brian Abrahams said the cash retention program replaces a guaranteed annual bonus.
He added it is unlikely the program is related to an upcoming phase 3 data release of Xpovio (selinexor) in endometrial cancer, adding he gives that trial a 65% possibility of success.

More on Karyopharm Therapeutics